Lenalidomide
Back to searchMolecule Structure
Scientific Name
Lenalidomide
Description of the Drug
Lenalidomide is a thalidomide derivative used to treat multiple myeloma and anemia in low to intermediate risk myelodysplastic syndrome.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-02-07 from
http://www.drugbank.ca/drugs/DB00480
http://www.drugbank.ca/drugs/DB00480
Brand Name(s)
Revlimid
Company Owner(s)
Arrow International Ltd, Celgene Corp
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| CRL4(CRBN) E3 ubiquitin ligase | PROTEIN COMPLEX | INHIBITOR | CHEMBL3833061 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL32978 | |
| PharmGKB | PA162363968 | |
| Human Metabolome Database | HMDB0014623 | |
| DrugBank | DB00480 | |
| PubChem: Thomson Pharma | 14847985 | |
| PubChem | 216326 | |
| Mcule | MCULE-9771679074 | |
| LINCS | LSM-6187 | |
| Nikkaji | J1.121.689G | |
| BindingDB | 65454 | |
| EPA CompTox Dashboard | DTXSID8046664 | |
| DrugCentral | 3317 | |
| ChemicalBook | CB3855432 | |
| Guide to Pharmacology | 7331 | |
| GSRS | 8bb063b4-594a-40a4-a344-1233a3d834d8 | |
| rxnorm | REVLIMID | LENALIDOMIDE |
| PubChem: Drugs of the Future | 12015317 | |
| ChEBI | 63791 |
